The DOI matches its Crossref record.
The natural history of vascular disease in homocystinuria and the effects of treatment
Abstract
Among 40 patients with homocystinuria due to cystathionine β‐synthase deficiency diagnosed in the state of New South Wales, Australia (population 6 million) and followed long‐term, there were 10 deaths at ages 2‐30 years. Of these 8 were definite vascular deaths, one was a presumed vascular death, and the other was due to an accident and unrelated to homocystinuria. The vascular deaths were all early cases and only one patient, a pyridoxine‐responsive 30‐year‐old woman, had been prescribed adequate treatment although it was uncertain that she was taking it. In 32 patients of mean age 30 years (range 9‐66 years) there were 539 patient‐years of treatment with pyridoxine, folic acid and hydroxocobalamin. There were 17 pyridoxine‐responsive patients and all maintained plasma total free homocyst(e)ine levels <200µmol/L over an average treatment period of 16.6 years. The 15 non‐responsive patients received additionally 6‐9 g of betaine daily. This resulted in a further 74% mean decline (±14% SD) in plasma total free homocyst(e)ine, persisting during an average (post‐betaine) treatment period of 11 years; current mean ± SD levels are 33 ± 17 µmol/L (n=15). There were two vascular events during treatment, one fatal pulmonary embolus (see above) and one myocardial infarction, whereas without treatment, 21 would have been expected, χ2 = 14.22, p = 0.0001, relative risk 0.09 (95% CI 0.02‐0.38). There were no events during 258 patient‐years of treatment in the 15 pyridoxine‐nonresponsive patients (p<0.005 versus expected untreated). Nineteen patients had a total of 19 major and 15 minor operations requiring anaesthetic, and three had successful pregnancies, one whilst receiving betaine. There were no thromboembolic complications. We conclude that treatment which effectively lowers circulating homocyst(e)ine, even to suboptimal levels, markedly reduces cardiovascular risk in patients with cystathionine β‐synthase deficiency, and that betaine therapy contributes importantly to this in pyridoxine‐nonresponsive patients. Betaine as additional therapy is safe and effective for at least 16 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
Wald, D. S., Law, M., & Morris, J. K. (2002) · BMJ · doi:10.1136/bmj.325.7374.1202 · Cited by 1,946
Craig, S. A. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.3.539 · Cited by 1,062
Homocysteine and vascular disease
Hankey, G. J., & Eikelboom, J. W. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11058-9 · Cited by 1,052
Brattström, L., Wilcken, D. E. L., Öhrvik, J., & Brudin, L. (1998) · Circulation · doi:10.1161/01.cir.98.23.2520 · Cited by 659
Self-citationThe controversy over homocysteine and cardiovascular risk
Ueland, P. M., Refsum, H., Beresford, S. A., & Vollset, S. E. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.2.324 · Cited by 517
Metadata
- Authors
- Wilcken, D. E. L., & Wilcken, B.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 1997-06
- Volume
- 20
- Issue
- 2
- Pages
- 295-300
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W1582000856
- Cited by
- 224
- References
- 0
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The natural history of vascular disease in homocystinuria and the effects of treatment. https://app.cochat.ai/papers/10.1023/a:1005373209964
- The paper
- Wilcken, D. E. L., & Wilcken, B. (1997). The natural history of vascular disease in homocystinuria and the effects of treatment. Journal of Inherited Metabolic Disease. https://doi.org/10.1023/a%3A1005373209964
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.